| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
N-Acetyl dapsone is the major metabolite of dapsone. Dapsone targets bacterial and protozoal folate synthesis. The acetylation of dapsone alters its pharmacokinetic and toxicological properties. The metabolite is used as a marker of dapsone metabolism.
|
|---|---|
| ln Vitro |
In vitro, N-acetyl dapsone is studied as the major metabolite of dapsone. It is used as a reference standard for the quantification of dapsone and its metabolites in biological samples. Its antibacterial and antiprotozoal activities are significantly reduced compared to the parent drug.
|
| ln Vivo |
In vivo, N-acetyl dapsone is the major metabolite of dapsone. Dapsone is used as an antibiotic for the treatment of leprosy, dermatitis herpetiformis, and other conditions. The metabolite is formed in the liver and excreted in urine. Its formation affects the pharmacokinetics and toxicity of dapsone.
|
| Enzyme Assay |
In vitro assays for N-acetyl dapsone typically involve its detection and quantification as a metabolite of dapsone. The compound is extracted from biological samples and analyzed by HPLC or LC-MS. It is used as a reference standard for pharmacokinetic studies and therapeutic drug monitoring.
|
| Cell Assay |
For in vitro cell assays, N-acetyl dapsone is not typically used as a treatment. It is used as a reference standard for the quantification of dapsone metabolites in cell culture supernatants or lysates. Cells are treated with dapsone, and the acetylated metabolite is quantified by LC-MS.
|
| Animal Protocol |
For in vivo animal studies, N-acetyl dapsone is studied as the major metabolite of dapsone. Animals are administered dapsone, and blood and tissue samples are collected. The compound is quantified by LC-MS. Its pharmacokinetic profile and formation are assessed in metabolic studies.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Monoacetyl dapsone is a known metabolite of dapsone in the human body. N-Acetyl dapsone (MW 290.34) has the molecular formula C₁₄H₁₄N₂O₃S. It is also known as MADDS and Monoacetyldapsone. The compound retains the sulfone core with an added acetyl group. It is stable under recommended storage conditions. |
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As a metabolite of dapsone, its toxicity profile is expected to be related to the parent drug. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Monoacetyldapsone is a secondary amide obtained by acetylation of aminophenyl sulfone. It is a sulfone, aniline, secondary amide, and also an acetamide compound. Its function is related to that of aminophenyl sulfone.
N-Acetyl dapsone (CAS# 565-20-8) is the major metabolite of the sulfonamide antibiotic dapsone. It has not been approved as a therapeutic agent. The compound is used as a reference standard in pharmacokinetic studies and therapeutic drug monitoring of dapsone. It is also known as MADDS and Monoacetyldapsone. |
| Molecular Formula |
C14H14N2O3S
|
|---|---|
| Molecular Weight |
290.34
|
| Exact Mass |
290.073
|
| CAS # |
565-20-8
|
| Related CAS # |
N-Acetyl dapsone-d4;2070015-08-4;N-Acetyl dapsone-d4-1;2070015-28-8;N-Acetyl dapsone-d8;1215635-13-4
|
| PubChem CID |
11257
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.362g/cm3
|
| Boiling Point |
589.5ºC at 760mmHg
|
| Melting Point |
238-240ºC
|
| Flash Point |
310.3ºC
|
| Index of Refraction |
1.641
|
| LogP |
3.795
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(NC1=CC=C(S(=O)(C2=CC=C(N)C=C2)=O)C=C1)=O
|
| InChi Key |
WDOCBIHNYYQINH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14N2O3S/c1-10(17)16-12-4-8-14(9-5-12)20(18,19)13-6-2-11(15)3-7-13/h2-9H,15H2,1H3,(H,16,17)
|
| Chemical Name |
N-[4-(4-aminophenyl)sulfonylphenyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4442 mL | 17.2212 mL | 34.4424 mL | |
| 5 mM | 0.6888 mL | 3.4442 mL | 6.8885 mL | |
| 10 mM | 0.3444 mL | 1.7221 mL | 3.4442 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
